Pfizer Canada today announced that its oral multi-targeted agent, Sutent (sunitinib malate) has been approved by Health Canada for the treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to intolerance or resistance. Pfizer's commitment to oncology research and the development of new cancer therapies delivers new hopes for patients with a rare form of cancer.
CNW Group (http://www.newswire.ca/en/releases/archive/May2006/31/c8794.html)
